SOURCE: Inspire Pharmaceuticals Inc.

October 21, 2010 06:30 ET

Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2010 Financial Results

DURHAM, NC--(Marketwire - October 21, 2010) -  Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to report third quarter 2010 financial results on Thursday, November 4, 2010 before the market opens. Inspire's President and CEO, Adrian Adams, and Executive Vice President and CFO, Thomas R. Staab, II, will host a conference call and live webcast with an accompanying slide presentation on Thursday, November 4, 2010 at 8:00 a.m. ET.

The live webcast and replay will be available on Inspire's website at www.inspirepharm.com. The webcast will include audio of the conference call and a slide presentation to be reviewed during the call. To access the conference call, U.S. participants may call (877) 648-7970 and international participants may call (706) 902-0415. The conference ID number is 17059925. A telephone replay of the conference call will be available until November 11, 2010. To access this replay, U.S. participants may call (800) 642-1687 and international participants may call (706) 645-9291. The conference ID number is 17059925.

About Inspire
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire's goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. Inspire's clinical pipeline includes denufosol tetrasodium for cystic fibrosis in Phase 3 development and AZASITE® (azithromycin ophthalmic solution) 1% for blepharitis in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. For more information, visit www.inspirepharm.com.

Contact Information

  • Investor Contact:
    Inspire Pharmaceuticals, Inc.

    Jenny Kobin
    VP, Investor Relations and Corporate Communications
    (919) 941-9777, Extension 219

    Media Contact:
    Inspire Pharmaceuticals, Inc.
    Cara Amoroso
    Assoc. Director, Corporate Communications
    (919) 941-9777, Extension 266